Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Company Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH. The company has also pursued antiviral programs targeting SARS-CoV-2 and other viral diseases. These products remain investigational and have not necessarily been approved for commercial use.

Founded in 2018 and headquartered in South San Francisco, California, Aligos conducts research and clinical-development activities through collaborations and trials in the United States and other international markets. Its work is focused primarily on advancing proprietary small-molecule medicines from discovery through clinical development.

Key Stats

• Today's Range: $1.92 to $2.32
• 50-Day Range: $1.98 to $6.22
• 52-Week Range: $1.92 to $13.69
• Volume: 120,520 shs
• Average Volume: 60,750 shs
• Market Capitalization: $12.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.50
• Consensus Rating: Moderate Buy

Aligos Therapeutics Stock Analysis - MarketRank™

Aligos Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 414th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aligos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aligos Therapeutics has a consensus price target of $38.50, representing about 1,844.4% upside from its current price of $1.98.

Amount of Analyst Coverage

Aligos Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aligos Therapeutics are expected to grow in the coming year, from ($6.61) to ($5.33) per share.

Price to Book Value per Share Ratio

Aligos Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.76% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 20.77, which indicates bearish sentiment.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 4.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aligos Therapeutics does not currently pay a dividend.

Dividend Growth

Aligos Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 0.96

News Sentiment

Aligos Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Aligos Therapeutics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for ALGS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.80% of the stock of Aligos Therapeutics is held by insiders.

Percentage Held by Institutions

60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALGS
• CIK: 1799448
• Web: www.aligos.com
• Phone: 800-466-6059
• Fax: N/A
• Employees: 82
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Aligos Therapeutics: $38.50
• High Price Target: $50.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,844.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.19 million
• Net Margins: -197.01%
• Pretax Margin: -186.65%
• Return on Equity: -206.30%
• Return on Assets: -99.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: $2.19 million
• Price / Sales: 5.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.81 per share
• Price / Book: 1.09

Miscellaneous

• Outstanding Shares: 6,240,000
• Free Float: 5,758,000
• Market Cap: $12.36 million
• Optionable: No Data
• Beta: 2.43